Nimesulene (Nimesulide)

• Nimesulide acts by inhibiting cyclo‑oxygenase‑2 mediated pathways, providing relief in several painful and inflammatory conditions.
• Pain: Alleviates acute and chronic pain by reducing prostaglandin‑mediated nociception.
• Fever: Lowers elevated body temperature through decreased prostaglandin E2 synthesis in the hypothalamus.
• Inflammation: Diminishes swelling and redness in musculoskeletal disorders by limiting inflammatory mediator production.
• Osteoarthritis: Improves joint function and reduces discomfort associated with osteoarthritic changes.

• Nimesulide selectively inhibits the cyclo‑oxygenase‑2 (COX‑2) enzyme, which catalyzes the conversion of arachidonic acid to prostaglandins involved in pain, fever and inflammation. By sparing COX‑1 activity, it maintains platelet function and gastric mucosal protection while reducing the synthesis of pro‑inflammatory prostaglandins, leading to its therapeutic effects. The drug binds reversibly to the COX‑2 active site, preventing access of substrate and thereby decreasing downstream eicosanoid production in inflamed tissues.

Nimesulide may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Nausea
• Dyspepsia
• Headache
• Dizziness
• Abdominal pain
• Rash
• Diarrhea
• Elevated liver enzymes

These events are typically mild and resolve after discontinuation.

Serious or Rare Side Effects

• Hepatotoxicity
• Severe skin reactions (Stevens‑Johnson syndrome or toxic epidermal necrolysis)
• Gastrointestinal bleeding or ulceration
• Acute renal failure
• Anaphylactic reactions
• Blood dyscrasias (e.g., agranulocytosis)

Prompt medical attention is required if any of these serious reactions occur.

• When prescribing Nimesulide, clinicians should observe several precautionary measures to minimize risk.
• Assess liver function: Perform baseline hepatic enzymes and monitor periodically during therapy.
• Avoid in patients with active peptic ulcer disease: NSAID‑related ulcer risk may be heightened.
• Limit duration: Use the lowest effective dose for the shortest necessary period.
• Caution in renal impairment: Adjust dosing and monitor renal function.
• Avoid in children under 12 years: Safety and efficacy not established.
• Store at ambient temperature: Keep below 25 °C in the original packaging, protected from moisture.

Nimesulide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Concurrent use with other NSAIDs or aspirin: Increases risk of gastrointestinal bleeding.
• Combination with anticoagulants (warfarin, heparin): Enhances anticoagulant effect and bleeding risk.
• Co‑administration with hepatotoxic drugs (e.g., isoniazid, methotrexate): May precipitate liver injury.
• Use with lithium: Can raise lithium serum concentrations.
• Use with methotrexate: May increase methotrexate toxicity.

Moderate Interactions (Monitor Closely)

• CYP2C9 inhibitors (e.g., fluconazole): May raise Nimesulide plasma levels.
• ACE inhibitors or ARBs: Potential for reduced renal function.
• Diuretics: May potentiate renal adverse effects.
• Selective serotonin reuptake inhibitors (SSRIs): Slightly increased bleeding risk.
• Beta‑blockers: May require blood pressure monitoring.